WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Mark Sabag Biography and Net Worth

Insider of Teva Pharmaceutical Industries

Mark Sabag was appointed Executive Vice President, International Markets Commercial, in 2021, leading all commercial activities in a region comprising 27 markets, including key Latin America countries, Russia and Eastern Europe, Israel, the Middle East, Africa, Asia-Pacific, China and Japan.

The International Markets commercial unit manages a high-quality portfolio of specialty medicines, generics and biopharmaceuticals, active pharmaceutical ingredients (API) and over-the-counter (OTC) products - with full end-to-end profit and loss (P&L) accountability.

Prior to that Mark served as Executive Vice President, Chief Human Resources Officer before his role was expanded to include Global Communications, Brand and ESG. Leading up to that he held several senior Human Resources positions for Teva’s International Group and Mergers and Acquisitions (M&As).

Before joining Teva in 2006, he held several senior global human resources roles at Intel Corporation.

Mark Sabag received a B.A. in economics and business management from Haifa University.

What is Mark Sabag's net worth?: The estimated net worth of Mark Sabag is at least $8.45 million as of March 5th, 2024. Mr. Sabag owns 382,590 shares of Teva Pharmaceutical Industries stock worth more than $8,451,413 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Sabag may own. Additionally, Mr. Sabag receives a salary of $1,730,000.00 as Insider at Teva Pharmaceutical Industries. Learn More about Mark Sabag's net worth.
How old is Mark Sabag?: Mr. Sabag is currently 53 years old. There are 6 older executives and no younger executives at Teva Pharmaceutical Industries. The oldest executive at Teva Pharmaceutical Industries is Mr. David R. Mcavoy J.D., Executive VP & Chief Legal Officer, who is 61 years old. Learn More on Mark Sabag's age.
What is Mark Sabag's salary?: As the Insider of Teva Pharmaceutical Industries Limited, Mr. Sabag earns $1,730,000.00 per year. There are 2 executives that earn more than Mr. Sabag. The highest earning executive at Teva Pharmaceutical Industries is Mr. Richard D. Francis, President, CEO & Director, who commands a salary of $6,710,000.00 per year. Learn More on Mark Sabag's salary.
How do I contact Mark Sabag?: The corporate mailing address for Mr. Sabag and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Mark Sabag's contact information.
Has Mark Sabag been buying or selling shares of Teva Pharmaceutical Industries?: Mark Sabag has not been actively trading shares of Teva Pharmaceutical Industries in the last ninety days. Most recently, Mark Sabag sold 100,000 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a transaction totalling $1,352,000.00. Following the completion of the sale, the executive vice president now directly owns 382,590 shares of the company's stock, valued at $5,172,616.80. Learn More on Mark Sabag's trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 984,382 shares worth more than $15,236,840.56. The most recent insider tranaction occured on November, 20th when EVP Christine Fox sold 19,388 shares worth more than $327,075.56. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 11/20/2024.

Mark Sabag Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2024	Sell	100,000	$13.52	$1,352,000.00	382,590
3/16/2021	Sell	127,244	$11.22	$1,427,677.68	20,598
2/13/2020	Sell	72,131	$13.03	$939,866.93
2/15/2018	Sell	5,050	$19.68	$99,384.00	44,517

Mark Sabag Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $22.09

$21.11

$22.17

50 Day Range

MA: $17.79

$16.44

$22.09

2 Week Range

Now: $22.09

$10.34

$22.17

Volume

12,760,563 shs

Average Volume

9,444,773 shs

Market Capitalization

$25.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Take these 4 steps today to protect your retirement NOW

Mark Sabag Biography and Net Worth

What is Mark Sabag's net worth?

How old is Mark Sabag?

What is Mark Sabag's salary?

How do I contact Mark Sabag?

Has Mark Sabag been buying or selling shares of Teva Pharmaceutical Industries?

Who are Teva Pharmaceutical Industries' active insiders?

Are insiders buying or selling shares of Teva Pharmaceutical Industries?